首页 > 市场调查报告书 > 製药

精神疾病

市场调查报告书

商品编码

1620256

全球发作性睡病药物市场规模：按给药途径、按应用、按地区、范围和预测

Global Narcolepsy Drugs Market Size By Route of Administration, By Application, By Geographic Scope And Forecast

出版日期: 2024年07月19日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格

简介目录

发作性睡病药物市场规模及预测

2023 年发作性睡病药物市场规模为 35 亿美元，预计在 2024-2030 年预测期间将以 10.1% 的复合年增长率增长，并在 2030 年达到 72 亿美元。

嗜睡症药物的全球市场推动因素

发作性睡病药物市场的市场推动因素可能受到多种因素的影响。

嗜睡症盛行率增加嗜睡症盛行率增加

发作性睡病是一种慢性神经系统疾病，其特征是白天过度嗜睡、猝倒和其他症状。随着对发作性睡病的诊断率和一般知识的提高，对发作性睡病的有效药物治疗的需求也在增加。

药物发现开发：

睡眠医学领域的研究和开发工作已经确定了治疗发作性睡病的新药物和方法。透过为患者提供更多的治疗选择，安全性、有效性和作用机制增强的新药的开发正在推动市场发展。

患者数增加：

医疗机构对发作性睡病的认识不断提高，以及未确诊病例的发现，导致寻求药物治疗的患者数量不断增加。随着医疗保健专业人员越来越擅长诊断和治疗发作性睡病，随着越来越多的人寻求发作性睡病的治疗，预计市场将会扩大。

增加知识与教育：

市场扩张的主要驱动力是对公众、护理人员、患者和医疗保健专业人员进行有关发作性睡病的教育。患者支持组织、宣传活动和教育计划都有助于增进理解、减少耻辱并鼓励早期诊断和治疗。

医疗支出增加：

嗜睡症药物保险覆盖范围和支付指南的增加，以及医疗保健支出的整体增加□□，使患者更容易接受治疗。医疗保健系统正在花费更多的资金来治疗发作性睡病等睡眠障碍，这增加了对药物干预措施的需求。

药物传输技术开发：

透皮贴片、鼻喷剂和缓释製剂等药物传递技术的进步正在提高发作性睡病治疗的便利性、依从性和有效性。这些发展改善了患者的健康并支持市场成长。

老年人口增加：

发作性睡病可以影响任何年龄层的任何人，但它通常首先出现在青春期或成年早期。随着世界人口老化以及越来越多的人进入老年人口，对发作性睡病相关治疗的需求预计将会增加。预计这将扩大市场。

提高市场渗透率：

製药公司透过向以前未开发的市场推出新产品以及建立策略联盟和合作伙伴关係，正在接触更多的人。需要增加市场渗透活动来接触弱势社区并促进整体市场扩张。

抑制全球发作性睡病药物市场的因素

有几个因素可能会成为发作性睡病药物市场的限制和挑战。其中包括：

治疗方案的限制：

虽然发作性睡病的治疗已取得进展，但可用的选择仍然有限。有些患者可能对目前的治疗反应不佳，导致治疗结果不佳，需要使用补充或替代疗法。

高昂的药品费用：

发作性睡病药物可能很昂贵，特别是对于无法获得医疗保健服务或保险不足的患者而言。过高的治疗费用可能会成为治疗依从性和可近性的障碍，特别是对于生活在医疗保健资源有限或社会经济失衡地区的人来说。

许多发作性睡病药物的副作用和耐受性问题可能会对患者的生活品质和药物依从性产生不利影响。头痛、噁心、头晕、失眠和情绪低落是典型的副作用。有些人可能觉得治疗的负面后果超过了正面后果，这可能会导致他们停止治疗或变得不遵从。

监理问题：

由于冗长的审批程序和严格的安全性和有效性标准等监管障碍，新的发作性睡病药物可能无法迅速进入市场。发作性睡病药物和替代疗法的市场发展可能会因监管审批和药物开发的延迟而受到限制。

误诊与诊断不足：

由于发作性睡病症状不明确，且往往与其他睡眠障碍共存，因此经常被误解或诊断不足。公众和医疗保健专业人员对发作性睡病的无知可能会导致诊断延迟和治疗不足，从而阻碍市场扩张。

社会议题与耻辱：

由于对发作性睡病的耻辱和误解，即使是发作性睡病患者也可能不愿就医或讨论他们的症状。发作性睡病药物的市场需求可能会受到社会耻辱的影响，这会影响患者的幸福感、寻求治疗的行为以及对医疗机构的参与。

复杂疾病照护：

行为治疗、药物治疗和生活方式改变对于发作性睡病（一种复杂的神经系统疾病）的整体护理都是必要的。治疗发作性睡病的复杂性给患者、其照护者和医疗保健专业人员带来了挑战，并可能影响治疗依从性和产业扩张。

新的治疗方案：

随着神经调节技术和替代疗法（例如失眠认知行为疗法（CBT-I））的发展，非药物方法可能可以用于治疗发作性睡病的症状。市场动态可能受到替代药物治疗与传统药物治疗的潜在竞争的影响。

医疗保健基础设施和访问：

这一领域的不平等，特别是在低收入和中等收入国家，可能会使患者更难接受发作性睡病的诊断和治疗。一些地区医疗设施不足、缺乏专门的睡眠诊所以及发作性睡病药物的供应有限可能会阻碍市场成长。

The market drivers for the Narcolepsy Drugs Market can be influenced by various factors. These may include: Growing Prevalence of Narcolepsy: One major factor driving the market is the increasing prevalence of narcolepsy, a chronic neurological condition marked by excessive daytime drowsiness, cataplexy, and other symptoms. The need for efficient pharmacological therapies for narcolepsy is growing as diagnosis rates rise and public knowledge of the condition grows.

Developments in Drug Discovery:

Research and development activities in the field of sleep medicine have resulted in the identification of new pharmacological drugs and narcolepsy treatment approaches. By giving patients more treatment alternatives, the development of new medications with enhanced safety profiles, efficacies, and modes of action propels market expansion.

Growing Patient Pool:

The number of patients seeking pharmaceutical therapies is rising as a result of the increased awareness of narcolepsy in healthcare settings and the discovery of undetected instances. The market is expected to rise as more people seek treatment for narcolepsy as medical professionals become more adept at diagnosing and treating the condition.

Increasing Knowledge and Education:

A major factor in the market's expansion is the work being done to educate the public, caregivers, patients, and healthcare professionals about narcolepsy. Patient support organizations, advocacy campaigns, and educational programs all contribute to greater understanding, less stigma, and the encouragement of early diagnosis and treatment.

Increasing Healthcare Spending:

Patients can receive therapy more easily thanks to rising insurance coverage and payment guidelines for narcolepsy medications, as well as an overall increase in healthcare spending. Healthcare systems are investing more money in treating sleep disorders, such as narcolepsy, which is driving up demand for pharmaceutical interventions.

Technological Developments in Drug Delivery:

Convenience, adherence, and efficacy of narcolepsy treatments are improved by advances in drug delivery technology, such as transdermal patches, intranasal sprays, and extended-release formulations. These developments increase patient happiness and support market growth.

Growing Senior Population:

Although narcolepsy can strike anyone at any age, it typically first appears in youth or early adulthood. The need for therapies related to narcolepsy is predicted to rise as the world's population ages and a greater percentage of people enter older age groups. This is expected to propel market expansion.

Increasing Market Penetration:

Pharmaceutical businesses are reaching a wider audience by launching new products in previously untapped markets and forming strategic alliances and partnerships. In order to reach disadvantaged communities and promote overall market expansion, increased market penetration activities are necessary.

Global Narcolepsy Drugs Market Restraints

Several factors can act as restraints or challenges for the Narcolepsy Drugs Market. These may include:

Restricted Treatment Options:

Although pharmaceutical treatments for narcolepsy have advanced, there are still only a few options accessible. Certain patients could not react well to current treatments, which could result in less-than-ideal treatment results and necessitate the use of complementary or alternative therapies.

Exorbitant Medications:

Narcolepsy medications can be costly, especially for those without access to healthcare services or sufficient insurance coverage. The exorbitant expense of pharmaceuticals may be an obstacle to treatment compliance and accessibility, particularly for those residing in areas with restricted healthcare resources or socioeconomic imbalances.

The quality of life and adherence of patients may be negatively impacted by the side effects and tolerability issues associated with many narcolepsy medications. A headache, nausea, dizziness, sleeplessness, and mood swings are typical adverse effects. Some people may find that the negative consequences of their treatment outweigh the positive results, which could result in treatment cessation or non-compliance.

Regulatory Difficulties:

New narcolepsy medications may not reach the market as soon as they would otherwise due to regulatory obstacles such as protracted approval procedures and strict safety and efficacy standards. Innovation in the narcolepsy drug market and treatment alternatives may be constrained by delays in regulatory clearances and drug development.

Misdiagnosis & Underdiagnosis:

Because of its vague symptoms and tendency to coexist with other sleep disorders, narcolepsy is frequently misunderstood or underdiagnosed. The general public's and healthcare professionals' ignorance of narcolepsy could lead to a delayed diagnosis and insufficient care, which would impede the market's expansion.

Social challenges and stigma:

People may be discouraged from getting medical attention or talking about their symptoms if they have narcolepsy due to stigma and misconceptions regarding the disorder. The market demand for narcolepsy medications can be impacted by social stigma, which can have an effect on patient well-being, treatment-seeking behavior, and involvement with healthcare facilities.

Complexity of Disease Care:

Behavioral therapies, medication, and lifestyle changes are all necessary for the entire care of narcolepsy, a neurological disorder that is complicated in nature. The complex nature of managing narcolepsy can provide difficulties for individuals with the condition, their carers, and medical professionals, thereby affecting treatment compliance and industry expansion.

Emerging Therapeutic Alternatives:

Non-pharmacological methods for treating narcolepsy symptoms may be made available by the development of alternative treatment modalities such as neuromodulation techniques and cognitive-behavioral therapy for insomnia (CBT-I). The dynamics of the market may be impacted by the possibility of competition from alternative medicines for conventional pharmaceutical treatments.

Healthcare Infrastructure and Access:

Inequalities in this area, especially in low- and middle-income nations, may make it more difficult for patients to receive a diagnosis and treatment for narcolepsy. Inadequate healthcare facilities, lack of specialized sleep clinics, and limited availability of narcolepsy drugs in certain regions could impede market growth.

Global Narcolepsy Drugs Market Segmentation Analysis

The Global Narcolepsy Drugs Market is Segmented on the basis of Route of Administration, Application, And Geography.

Narcolepsy Drugs Market, By Route of Administration

Oral:
Convenient and simple to use, this is the most popular method of administering narcolepsy medications.
Intravenous (IV):
Because of the possibility of abuse, this method is mostly used for sodium oxybate, which is given at nighttime in a supervised environment.

Narcolepsy Drugs Market, By Application

Excessive Daytime Sleepiness (EDS):
The main symptom of narcolepsy is excessive daytime sleepiness (EDS), for which the majority of drugs aim to increase alertness and wakefulness.
Cataplexy:
The medications covered in this section are specially designed to tackle sudden, emotionally-induced muscle weakness.
Sleep Paralysis:
Certain drugs may be able to lessen the frequency and length of bouts of sleep paralysis.

Narcolepsy Drugs Market, By Geography

North America:
Has the biggest market share because of its well-established healthcare system, high level of awareness, and easy access to new drugs.
Europe:
Expanding market with rising innovative treatment options uptake and awareness.
Asia Pacific:
Growing rates of diagnosis and increased disposable income have created opportunities for this emerging industry to grow significantly.
Rest of the World:
The remainder of the world, which comprises nations in Africa, the Middle East, and Latin America, has differing degrees of market development and access to narcolepsy drugs.

Key Players

The major players in the Narcolepsy Drugs Market are:
Jazz Pharmaceuticals
Teva Pharmaceutical Industries Ltd
Sun Pharma Laboratories Ltd
Actelion Pharmaceuticals Ltd
Avadel Pharmaceuticals Inc
Harmony Biosciences
Minerva Neurosciences Inc
Cephalon Inc.

1. Introduction

Market Definition
Market Segmentation
Research Methodology

2. Executive Summary

Key Findings
Market Overview
Market Highlights

3. Market Overview

Market Size and Growth Potential
Market Trends
Market Drivers
Market Restraints
Market Opportunities
Porter's Five Forces Analysis

4. Narcolepsy Drugs Market, By Route of Administration

Oral
Intravenous (IV)

5. Narcolepsy Drugs Market, By Application

Excessive Daytime Sleepiness (EDS)
Cataplexy
Sleep Paralysis

6. Regional Analysis

North America
United States
Canada
Mexico
Europe
United Kingdom
Germany
France
Italy
Asia-Pacific
China
Japan
India
Australia
Latin America
Brazil
Argentina
Chile
Middle East and Africa
South Africa
Saudi Arabia
UAE

7. Market Dynamics

Market Drivers
Market Restraints
Market Opportunities
Impact of COVID-19 on the Market

8. Competitive Landscape

Key Players
Market Share Analysis

9. Company Profiles

Jazz Pharmaceuticals
Teva Pharmaceutical Industries Ltd
Sun Pharma Laboratories Ltd
Actelion Pharmaceuticals Ltd
Avadel Pharmaceuticals Inc
Harmony Biosciences
Minerva Neurosciences Inc
Cephalon Inc.

10. Market Outlook and Opportunities

Emerging Technologies
Future Market Trends
Investment Opportunities

11. Appendix

List of Abbreviations
Sources and References

02-2729-4219

+886-2-2729-4219

License/价格

全球发作性睡病药物市场规模：按给药途径、按应用、按地区、范围和预测

Global Narcolepsy Drugs Market Size By Route of Administration, By Application, By Geographic Scope And Forecast

发作性睡病药物市场规模及预测

目录

第1章简介

第 2 章执行摘要

第3章市场概述

第 4 章发作性睡病药物市场：依给药途径

第5章发作性睡病药物市场：依应用分类

第6章区域分析

第7章市场动态

第8章竞争态势

第9章公司简介

第 10 章市场前景与机会

第11章市场展望附录

Narcolepsy Drugs Market Size And Forecast